ClinicalTrials.gg
CompletedNCT05372653Updated Mar 30, 2025Results posted

A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis

A Phase 3 interventional study of OPA-15406 in Atopic Dermatitis (AD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 3 Months to 2 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
3 Months to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.

Enrollment
14th of 16
41 · median 177
Started
2022
with 2 others
Phase 3
10 of 16
2 open now
Registered
10th of 16
by date
Lead sponsor
9 of 16
Otsuka Pharmaceutical Co., Ltd.

Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 14th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 3, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difamilast

difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 3 Months to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing difamilast in Dermatitis, Atopic, or all of them as a file.
02

Study summary

To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
3 Months to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are diagnosed with AD in accordance with the criteria of the Japanese Dermatological Association
  • Subjects whose AD affects 5% to 40% of BSA (excluding scalp) at the screening and baseline examinations
  • Subjects who have an IGA score of 2 or 3 at the screening and baseline examinations

Exclusion criteria

Exclusion Criteria:

-Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    OPA-15406

    Drug: OPA-15406

Interventions

  • 0.3% or 1% ointment, topical, twice daily, for 52 weeks

    Also known as: difamilast

06

What researchers measure

Primary outcomes

  1. Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades)

    The investigator or sub investigator assessed the skin symptoms using IGA (Investigator's Global Assessment). The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA was defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.

    Time frame: Week 4

Secondary outcomes

  1. Response Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI)

    Response (improvement) in EASI 75 was defined as a decrease by ≥75% in the percent change from baseline in the total score of EASI.

    Time frame: Week4

07

Results

Posted Mar 30, 2025

Participant flow

Participant flow — Overall Study
Milestone0.3% OPA-154061% OPA-15406
Started1229
Completed1125
Not completed14
Withdrew: Study treatment terminated by parent/guardian13
Withdrew: Adverse event01

Outcome measures

PrimarySuccess Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades)

The investigator or sub investigator assessed the skin symptoms using IGA (Investigator's Global Assessment). The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA was defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.

Time frame:
Week 4
Reported as:
Number · Percentage of perticipants
Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades)
Percentage of perticipants0.3% OPA-15406
Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades)56.10 (39.75 to 71.53)
SecondaryResponse Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI)

Response (improvement) in EASI 75 was defined as a decrease by ≥75% in the percent change from baseline in the total score of EASI.

Time frame:
Week4
Reported as:
Number · Percentage of perticipants
Response Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI)
Percentage of perticipants0.3% OPA-15406
Response Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI)82.93 (67.94 to 92.85)

Adverse events

Collected over Adverse event collection begins after a legal guardian signs the ICF, and continues until the completion of the 52-week follow-up examination (or the final observation day).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.3% OPA-154060/41 (0%)1/41 (2.4%)24/41 (58.5%)
1% OPA-154060/29 (0%)1/29 (3.4%)29/29 (100%)
Most frequent serious events
Most frequent serious events
Event0.3% OPA-154061% OPA-15406
Kawasaki's diseaseVascular disorders0/411/29
Respiratory syncytial virus infectionInfections and infestations1/410/29
Most frequent other events
Showing 10 of 40
Most frequent other events
Event0.3% OPA-154061% OPA-15406
NasopharyngitisInfections and infestations18/4124/29
GastroenteritisInfections and infestations4/4116/29
Dermatitis diaperSkin and subcutaneous tissue disorders0/4110/29
Otitis media acuteInfections and infestations0/418/29
Dermatitis contactSkin and subcutaneous tissue disorders8/418/29
COVID-19Infections and infestations4/417/29
Conjunctivitis bacterialInfections and infestations0/416/29
FolliculitisInfections and infestations0/415/29
Hand-foot-and-mouth diseaseInfections and infestations0/415/29
ConstipationGastrointestinal disorders0/414/29

Baseline characteristics

Age, Continuous
Age, Continuous(Months)0.3% OPA-154061% OPA-15406Total
Mean7.9 ± 3.910.8 ± 5.410.0 ± 5.1
Age, Customized
Age, Customized(Participants)0.3% OPA-154061% OPA-15406Total
Age Group — <12 months101828
Age Group — >=12 months21113
Sex: Female, Male
Sex: Female, Male(Participants)0.3% OPA-154061% OPA-15406Total
Female51015
Male71926
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)0.3% OPA-154061% OPA-15406Total
Japanese122941
Region of Enrollment
Region of Enrollment(participants)0.3% OPA-154061% OPA-15406Total
Japan122941
08

Study locations

1 site
  • Sotobo Children's Clinic
    Isumi, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Dec 2022, 7 months.

Results were first posted in Mar 2025, 2 years 3 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 7 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 13, 2022
StartActual
May 23, 2022
Primary completionActual
Dec 29, 2022
CompletionActual
Nov 29, 2023
Results first posted
Mar 30, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05372653
Responsible party
Sponsor
First posted
May 13, 2022
Start date
May 23, 2022
Primary completion
Dec 29, 2022
Completion
Nov 29, 2023
Results posted
Mar 30, 2025
Last update
Mar 30, 2025

Study contacts

Takehisa Matsumaru
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difamilast

Start the discussion